There might soon be a new weight loss treatment king on top. This week, Eli Lilly posted the first large-scale trial results of its experimental combination drug retatrutide—and it’s a whopper of a success.

Retatrudide. Say that fast five times. Okay, sure, it doesn’t exactly roll off the tongue, but as a weight loss medication, it’s kicking ass in clinical trials. According to the company, people with obesity and knee osteoarthritis taking retatrutide lost up to 71 pounds on average, or nearly 30% of their baseline weight. The weight loss results appear to be the best ever documented for an obesity medication so far and should pave the way toward retatrutide’s regulatory approval in the near future.

“We are encouraged by the results of TRIUMPH-4, which highlight the powerful effect of r

See Full Page